Post-IPO Strength Seen In Stemline Therapeutics
Investor demand for shares of Stemline Therapeutics (NASDAQ: STML) seems to be picking up tremendously, as the stock rallied 13.3% higher yesterday to reach a new high of $16.49 per share in yesterday's trading (May 1st, 2013). This represents a 65% premium over its IPO price of $10.00 per share, and shows that there has been significant investment interest from the market since January 2013. Through the public offering, Stemline collected $38.15 M in proceeds. Based on the statements of CEO Dr. Ivan Bergstein, this should provide the company with the funds needed to meet the next key milestones for its SL-401 and SL-701 development programs.
Stemline Therapeutics' anti-cancer programs offer a unique play on the cell therapy and oncology sector with proprietary technology that targets solid tumors and cancer stem cells (CDCs). The CSCs are a particularly important for the next generation of cancer therapeutics due to their central role in tumor relapses.
SL-701 is a cancer vaccine that is being developed as a treatment of advanced pediatric and adult brain cancer (glioma), and is close to advancing into Phase IIb trial for both the pediatric and adult indications soon. This therapy is specifically designed to induce an immune system response against particular factors expressed by CSCs and the tumors found in glioma. Since treatment options are very limited for the more aggressive types of brain cancer, SL-701 could ultimately become a very successful product for a niche market.
SL-401 is a biologic that directly attacks cancer, and is directed towards a particular receptor known as IL-3R (interleukin-3 receptor) that is overexpressed on cancer stem cells as well as more matured cancer cells in certain types of hematologic (blood) cancers. Capitalizing on the SL-401's affinity for particular blood cancers, Stemline is looking to pursue clinical development these indications (and possibly more): Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Chronic Myeloid Leukemia (CML)
Of these indications, BPDCN could be of particularly interest in the next few years since this type of blood cancer only affects 2,000 patients each year and result in accelerated approval for SL-401.
Overall, STML looks like another interesting mid-stage play on cancer therapeutics. The company's focus on cancer stem cell targeting with SL-701 and SL-401 makes sense in the context of cancer treatment as a whole. Safety and tolerability of the two therapeutics has also been generally established in early-stage trials, and each of the two therapies have established a niche indication that could significantly improve patient outcomes while generating significant revenue for Stemline shareholders.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.